Study on the Safety of Rho-kinase Inhibitor (Ripasudil) with Needling

Phase 2

• Conditions: Glaucoma; D005901

• Registration Number: JPRN-jRCTs061220032
• Lead Sponsor: Mizuno Yu

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2022-06-09
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

The study will be open to those who confirm all of the following criteria
(1) Patients undergoing needling at least 3 months after trabeculectomy.
(2) Patients must be at least 20 years of age at the time of consent.
(3) Patients who can make outpatient visits for 3 months after needling.
(4) Patients who can write consent to participate in this study.

Exclusion Criteria

Patients who relevant to any of the following criteria are not eligible for this study.
(1) Pregnant, lactating or possibly pregnant women.
(2) Patients who have difficulty measuring intraocular pressure with a Goldmann applanation tonometer.
(3) Patients with allergy to Ripasudil.
(4) Patients less than 3 months post-internal eye surgery (except for cataract surgery performed at the same time with trabeculectomy).
(5) Patients with a history of conjunctival surgery (except for trabeculectomy).
(6) Patients who have received eye drops or oral medication containing tranilast at least 30 days prior to the start of the study.
(7) Patients receiving ripasudil ophthalmic solution at least 3 days prior to the start of the study
(8) Other patients deemed inappropriate by the principal investigator/approving ophthalmologist to conduct this study.
(9) Patients who are participating or intend to participate in other clinical studies while participating in this study.

Study & Design

• Study Type: Interventional
• Study Design: Not specified